Loading stock…

WuXi Biologics (Cayman) Inc. (2269) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

WuXi Biologics (Cayman) Inc.

2269Market cap $30BPrice $7.0

Country🇨🇳China

SectorHealthcare

IndustryLife Sciences

Manufactures biologic drugs and vaccines for global pharma clients through its "Follow the Molecule" model, tracking a project from lab to commercial scale. Its bioreactor capacity ranks among the world's largest, powering therapies for millions of patients worldwide.

In Bastion Portfolios?

52W Return+54%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+12%7

Revenue Forecast

Rev CAGR (1y)+23%8

Rev CAGR (3y)+19%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+1+37%9

EPS Growth Y+2+20%8

EPS Growth Y+3+21%8

Quality

Margins

EBIT Margin32%9

Net Income Margin21%8

Free Cash Flow Margin18%8

Debt

Net Debt/EBITDA-1.110

Efficiency

ROE11%5

ROA9%8

Earnings Stability77

GEAR+STRONG84

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)282

P/E Ratio (Forward 3y)203

P/BV4.14

EV Multiples

EV/EBITDA Fwd202

EV/EBIT Fwd233

Yield

Free Cash Flow Yield2.2%4

Dividend Yieldna–

Momentum

Short term

1 month return+15%10

3 month return+59%10

YTD return+80%10

Mid term

Price vs 52wHigh94%9

1 year return+35%8

Long term

3 year return+30%4

5 year return-49%1

Risk Shield

Price Risk

Beta1.42

Volatility45%4

Free Cash Flow

Free Cash Flow Margin18%8

Free Cash Flow Yield2.2%4

Quality

ROCE14%7

Earnings Stability77

Net Debt/EBITDA-1.110

02Growth

Is it actually growing, and how fast?

2269WuXi Biologics (Cayman)

Revenue FY25$3.1B

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+23%8

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+37%9

EPS growth, FY27E+20%8

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 12%/yr over the last 3 years and is set to grow 19%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 19%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

2269WuXi Biologics (Cayman)

Total return Current273%

Price return Current273%

MOMENTUM RATING↗

STRONG78 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+59%10

YTD return+80%10

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+35%8

3-year return+30%4

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+59%) and so far this year (+80%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+30% over three years and -49% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on WuXi Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

2269WuXi Biologics (Cayman)

Revenue FY25$3.1B

GROWTH RATING↗

VERY STRONG88 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+12%7

Revenue, next 1Y+23%8

Revenue, next 3Y, CAGR+19%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+37%9

EPS growth, FY27E+20%8

EPS growth, FY28E+21%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 88% of companies worldwide.

Revenue grew 12%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 19%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 12%/yr over the last 3 years and is set to grow 19%/yr from here.

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 21%/yr vs revenue 19%/yr).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

2269WuXi Biologics (Cayman)

Total return Current273%

Price return Current273%

MOMENTUM RATING↗

STRONG78 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+15%10

3-month return+59%10

YTD return+80%10

MID & LONG-TERM▾SCORE

% of 52-week high94%9

1-year return+35%8

3-year return+30%4

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 35% over the past year, now 6% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+15%), over three months (+59%) and so far this year (+80%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+30% over three years and -49% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on WuXi Biologics. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community